Abstract
Atherosclerosis was relatively uncommon 100 years ago, when researchers first established its link to elevated cholesterol. As the twentieth century progressed, however, factors such as high‐fat diets, sedentary lifestyles, cigarette smoking, and urbanization combined to increase the prevalence of both hypercholesterolemia and coronary heart disease (CHD) throughout the developed world. Atherogenesis begins at an early age and progresses throughout life, and cholesterol levels during young adulthood strongly predict the risk of CHD and related mortality during the ensuing decades. The total cholesterol level in youth also determines the actual age at which a critical level of atherosclerosis will be reached. Early studies on the primary and secondary prevention of CHD failed to identify a linear relationship between lipid lowering and risk reduction, primarily because older lipid‐lowering agents lacked the potency to reduce cholesterol levels significantly enough to achieve lower cardiovascular event and mortality rates. The introduction of the statins, with their powerful lipid‐lowering activity, overcame this limitation. Several large‐scale trials of statins firmly established the efficacy of these agents in both primary and secondary CHD prevention. With the availability of statin therapy, we are now able to reduce the risk of major adverse CHD events by an average of 30%, regardless of patient age or gender.
Keywords: atherosclerosis, hypercholesterolemia, statins
Full Text
The Full Text of this article is available as a PDF (53.7 KB).
References
- 1. Haust MD, More RH: Development of modern theories on the pathogenesis of atherosclerosis In The Pathogenesis of Atherosclerosis (Eds. Wissler RW, Geer JC.), p. 1–19. Baltimore, Md.: Williams and Wilkins, 1972. [Google Scholar]
- 2. Murray CJ, Lopez AD: Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997; 349: 1269–1276 [DOI] [PubMed] [Google Scholar]
- 3. Saito Y: Prevention of coronary heart diseases and lipid‐lowering therapy in Japan. Eur Heart J 2000; 2 (suppl D): D49–D50 [Google Scholar]
- 4. Kawate R, Yamakido M, Nishimoto Y, Bennett PH, Hamman RF, Knowler WC: Diabetes mellitus and its vascular complications in Japanese migrants on the island of Hawaii. Diabetes Care 1979; 2: 161–170 [DOI] [PubMed] [Google Scholar]
- 5. Enos WF, Holmes RH, Beyer J: Coronary disease among United States soldiers killed in action in Korea. Preliminary report. J Am Med Assoc 1953; 152: 1090–1093 [DOI] [PubMed] [Google Scholar]
- 6. McNamara JJ, Molo MA, Stremple JF, Cutting RT: Coronary artery disease in combat casualties in Vietnam. J Am Med Assoc 1971; 216: 1185–1187 [PubMed] [Google Scholar]
- 7. Strong JP, Malcom GT, McMahan CA, Tracy RE, Newman WP III, Herderick EE, Cornhill JF: Prevalence and extent of atherosclerosis in adolescents and young adults. Implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. J Am Med Assoc 1999; 281: 727–735 [DOI] [PubMed] [Google Scholar]
- 8. Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking . A preliminary report from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. J Am Med Assoc 1990; 264: 3018–3024 [DOI] [PubMed] [Google Scholar]
- 9. Klag MJ, Ford DE, Mead LA, He J, Whelton PK, Liang KY, Levine DM: Serum cholesterol in young men and subsequent cardiovascular disease. N Engl J Med 1993; 328: 313–318 [DOI] [PubMed] [Google Scholar]
- 10. Okayama A, Ueshima H, Marmot MG, Nakamura M, Kita Y, Yamakawa M: Changes in total serum cholesterol and other risk factors for cardiovascular disease in Japan, 1980–1989. Int J Epidemiol 1993; 22: 1038–1047 [DOI] [PubMed] [Google Scholar]
- 11. Grundy SM: Cholesterol and coronary heart disease. A new era. J Am Med Assoc 1986; 256: 2849–2858 [PubMed] [Google Scholar]
- 12. Levine GN, Keaney JF Jr, Vita JA: Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med 1995; 332: 512–521 [DOI] [PubMed] [Google Scholar]
- 13. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. J Am Med Assoc 1998; 279: 1615–1622 [DOI] [PubMed] [Google Scholar]
- 14. Long‐Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group : Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–1357 [DOI] [PubMed] [Google Scholar]
- 15. Sacks FM, Pfeffer MA, Moyé LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C, Davis B, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators : The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001–1009 [DOI] [PubMed] [Google Scholar]
- 16. Scandinavian Simvastatin Survival Study Group : Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389 [PubMed] [Google Scholar]
- 17. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301–1307 [DOI] [PubMed] [Google Scholar]
- 18. LaRosa JC, He J, Vupputuri S: Effect of statins on risk of coronary disease: A meta‐analysis of randomized controlled trials. J Am Med Assoc 1999; 282: 2340–2346 [DOI] [PubMed] [Google Scholar]